IPSEN (OTCMKTS:IPSEY – Get Free Report) was the target of a large decline in short interest in April. As of April 30th, there was short interest totaling 297 shares, a decline of 39.6% from the April 15th total of 492 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 680 shares, the days-to-cover ratio is presently 0.4 days.
IPSEN Stock Performance
OTCMKTS IPSEY traded down $0.10 during trading on Friday, reaching $48.76. The company’s stock had a trading volume of 109 shares, compared to its average volume of 870. IPSEN has a 12 month low of $28.59 and a 12 month high of $51.10. The firm has a 50 day moving average price of $47.22 and a 200 day moving average price of $41.56.
Analyst Upgrades and Downgrades
Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Read More
- Five stocks we like better than IPSEN
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
